New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 12, 2012
08:34 EDTIMMUImmunomedics' Epratuzumab in Lupus showed long-term efficacy and safety
Immunomedics announced that patients with moderate-to-severe lupus who had received continued cycles of epratuzumab therapy maintained improvements or further improved their lupus disease activity over a timeframe of approximately 4 years. Importantly, lower levels of median corticosteroid use were also maintained throughout the study. Results from this open-label, single-arm extension study of the Phase III ALLEVIATE trials were reported by clinical investigators at the 2012 American College of Rheumatology Annual Scientific Meeting in Washington DC. Immunomedics has licensed the rights to the development and commercialization of epratuzumab to UCB in all autoimmune diseases.
News For IMMU From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 5, 2016
12:33 EDTIMMUImmunomedics upgraded to Outperform from Market Perform at Wells Fargo
Subscribe for More Information
09:32 EDTIMMUImmunomedics granted breakthrough therapy designation for sacituzumab govitecan
Immunomedics announced that its lead investigational antibody-drug conjugate, sacituzumab govitecan, or IMMU-132, has received Breakthrough Therapy Designation from the FDA for the treatment of patients with triple-negative breast cancer who have failed at least 2 prior therapies for metastatic disease.
09:29 EDTIMMUImmunomedics granted Breakthrough Therapy Designation from FDA for IMMU-132
Subscribe for More Information
February 3, 2016
16:05 EDTIMMUImmunomedics sees Phase 3 PANCRIT-1 trial completing enrollment in 2016
Subscribe for More Information
16:03 EDTIMMUImmunomedics reports Q2 EPS (15c), two estimates (14c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use